NCT01712919

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Jiangsu Cancer Institute & Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
RADIATION	Intensity-modulated radiotherapy	Patients will be given intensity-modulated radiotherapy(IMRT)
DRUG	Concurrent chemotherapy with paclitaxel and nedaplatin	Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
BIOLOGICAL	Cetuximab	Patients will be given cetuximab weekly during radiation therapy

Timeline

• Start date: 2010-05-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2012-10-24
• Last updated: 2014-03-24

Locations

1 site across 1 country: China